The Analysis of Inflammation-Related Proteins in a Cargo of Exosomes Derived from the Serum of Uveal Melanoma Patients Reveals Potential Biomarkers of Disease Progression

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Jul 20

PMID 34283046

Citations 15

Authors

Joanna Patrycja Wroblewska

Michal Stefan Lach

Katarzyna Kulcenty

Lukasz Galus

Wiktoria Maria Suchorska

Daniel Rosel

Jan Brabek

Andrzej Marszalek

Affiliations

Soon will be listed here.

Abstract

Background: Uveal melanoma (UM) is the most common intraocular tumour in adults with a poor prognosis and extremely high mortality rate due to the development of metastatic disease. However, despite relatively good knowledge about the histological and genetic risk factors for metastasis development, there is no specific biomarker that would allow early detection of UM progression. Recently, exosomes and their molecular cargo have been widely studied in the search for potential biomarkers in several cancers. The purpose of this study was to analyze the inflammation-related protein cargo of exosomes derived from the serum of primary and metastatic UM patients and healthy donors.

Methods: The exosomes were isolated from the serum of primary and metastatic UM patients and healthy donors. Using multiplex immunoassay technology, we analyzed the concentration of 37 inflammation-related proteins in obtained exosomes.

Results: The analysis of protein cargo showed several molecules related to inflammation, such as interferon-gamma, interleukin 2, 22 and 12(p40), Pentraxin-3, TNFSF13B and TNFSF8 which were significantly enriched in metastatic UM exosomes. We showed a significant correlation between the disease stage and the concentration of these inflammation-related proteins from exosomal cargo.

Conclusions: Based on the obtained results, we propose the panel of exosomal proteins for early detection of uveal melanoma progression into metastatic disease.

Citing Articles

The Effect of Ionising Radiation on the Properties of Tumour-Derived Exosomes and Their Ability to Modify the Biology of Non-Irradiated Breast Cancer Cells-An In Vitro Study.

Lach M, Wroblewska J, Michalak M, Budny B, Wrotkowska E, Suchorska W Int J Mol Sci. 2025; 26(1.

PMID: 39796230 PMC: 11719956. DOI: 10.3390/ijms26010376.

Exosomes are the mediators between the tumor microenvironment and prostate cancer (Review).

Wu Y, Wang X, Zeng Y, Liu X Exp Ther Med. 2024; 28(6):439.

PMID: 39355518 PMC: 11443591. DOI: 10.3892/etm.2024.12728.

Advances in Extracellular-Vesicles-Based Diagnostic and Therapeutic Approaches for Ocular Diseases.

Su Y, Chen M, Xu W, Gu P, Fan X ACS Nano. 2024; 18(34):22793-22828.

PMID: 39141830 PMC: 11363148. DOI: 10.1021/acsnano.4c08486.

Recent Advances in Molecular and Genetic Research on Uveal Melanoma.

Fuentes-Rodriguez A, Mitchell A, Guerin S, Landreville S Cells. 2024; 13(12.

PMID: 38920653 PMC: 11201764. DOI: 10.3390/cells13121023.

Dynamic interactions in the tumor niche: how the cross-talk between CAFs and the tumor microenvironment impacts resistance to therapy.

Piwocka O, Piotrowski I, Suchorska W, Kulcenty K Front Mol Biosci. 2024; 11:1343523.

PMID: 38455762 PMC: 10918473. DOI: 10.3389/fmolb.2024.1343523.

References

Wroblewska J, Lach M, Ustaszewski A, Kulcenty K, Ibbs M, Jagiello I . The Potential Role of Selected miRNA in Uveal Melanoma Primary Tumors as Early Biomarkers of Disease Progression. Genes (Basel). 2020; 11(3). PMC: 7140886. DOI: 10.3390/genes11030271. View

El-Tanani M, Yuen H, Shi Z, Platt-Higgins A, Buckley N, Mullan P . Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells. Cancer Sci. 2010; 101(6):1354-60. PMC: 11158710. DOI: 10.1111/j.1349-7006.2010.01561.x. View

Tugues S, Burkhard S, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J . New insights into IL-12-mediated tumor suppression. Cell Death Differ. 2014; 22(2):237-46. PMC: 4291488. DOI: 10.1038/cdd.2014.134. View

An T, Qin S, Xu Y, Tang Y, Huang Y, Situ B . Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. J Extracell Vesicles. 2015; 4:27522. PMC: 4475684. DOI: 10.3402/jev.v4.27522. View

Setrerrahmane S, Xu H . Tumor-related interleukins: old validated targets for new anti-cancer drug development. Mol Cancer. 2017; 16(1):153. PMC: 5606116. DOI: 10.1186/s12943-017-0721-9. View

Tsering T, Laskaris A, Abdouh M, Bustamante P, Parent S, Jin E . Uveal Melanoma-Derived Extracellular Vesicles Display Transforming Potential and Carry Protein Cargo Involved in Metastatic Niche Preparation. Cancers (Basel). 2020; 12(10). PMC: 7600758. DOI: 10.3390/cancers12102923. View

Jager M, Shields C, Cebulla C, Abdel-Rahman M, Grossniklaus H, Stern M . Uveal melanoma. Nat Rev Dis Primers. 2020; 6(1):24. DOI: 10.1038/s41572-020-0158-0. View

Thery C, Witwer K, Aikawa E, Alcaraz M, Anderson J, Andriantsitohaina R . Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2019; 7(1):1535750. PMC: 6322352. DOI: 10.1080/20013078.2018.1535750. View

Greten F, Grivennikov S . Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019; 51(1):27-41. PMC: 6831096. DOI: 10.1016/j.immuni.2019.06.025. View

10.

Berus T, Halon A, Markiewicz A, Orlowska-Heitzman J, Romanowska-Dixon B, Donizy P . Clinical, Histopathological and Cytogenetic Prognosticators in Uveal Melanoma - A Comprehensive Review. Anticancer Res. 2017; 37(12):6541-6549. DOI: 10.21873/anticanres.12110. View

11.

Rathore M, Girard C, Ohanna M, Tichet M, Ben Jouira R, Garcia E . Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway. Oncogene. 2019; 38(30):5873-5889. DOI: 10.1038/s41388-019-0848-9. View

12.

Lejeune F, Lienard D, Matter M, Ruegg C . Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 2006; 6:6. View

13.

Taha E, Sogawa C, Okusha Y, Kawai H, Oo M, Elseoudi A . Knockout of MMP3 Weakens Solid Tumor Organoids and Cancer Extracellular Vesicles. Cancers (Basel). 2020; 12(5). PMC: 7281240. DOI: 10.3390/cancers12051260. View

14.

Takov K, Yellon D, Davidson S . Comparison of small extracellular vesicles isolated from plasma by ultracentrifugation or size-exclusion chromatography: yield, purity and functional potential. J Extracell Vesicles. 2019; 8(1):1560809. PMC: 6327926. DOI: 10.1080/20013078.2018.1560809. View

15.

Cooper A, Khader S . IL-12p40: an inherently agonistic cytokine. Trends Immunol. 2006; 28(1):33-8. DOI: 10.1016/j.it.2006.11.002. View

16.

Johnstone C, Chand A, Putoczki T, Ernst M . Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer. Cytokine Growth Factor Rev. 2015; 26(5):489-98. DOI: 10.1016/j.cytogfr.2015.07.015. View

17.

Damento G, Pulido J, Abbott B, Hodge D, Dalvin L . TNF-Alpha Inhibition and Other Immunosuppressants in the Development of Uveal and Cutaneous Melanoma. Mayo Clin Proc. 2019; 94(7):1287-1295. DOI: 10.1016/j.mayocp.2018.11.033. View

18.

Surman M, Hoja-Lukowicz D, Szwed S, Kedracka-Krok S, Jankowska U, Kurtyka M . An Insight into the Proteome of Uveal Melanoma-Derived Ectosomes Reveals the Presence of Potentially Useful Biomarkers. Int J Mol Sci. 2019; 20(15). PMC: 6695883. DOI: 10.3390/ijms20153789. View

19.

Lane A, Egan K, Harmon D, Holbrook A, Munzenrider J, Gragoudas E . Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology. 2009; 116(11):2206-12. DOI: 10.1016/j.ophtha.2009.04.044. View

20.

Putoczki T, Ernst M . IL-11 signaling as a therapeutic target for cancer. Immunotherapy. 2015; 7(4):441-53. DOI: 10.2217/imt.15.17. View